advertisement

Topcon

Supuran CT 13

Showing records 1 to 13 | Display all abstracts from Supuran CT

82535 Rho-kinase inhibitors in the management of glaucoma
Berrino E
Expert Opinion on Therapeutic Patents 2019; 29: 817-827
82353 Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)
Nocentini A
Expert Opinion on Therapeutic Patents 2019; 29: 805-815
82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Bonardi A
Expert Opinion on Therapeutic Patents 2019; 29: 753-759
82395 Diagnostic markers for glaucoma: a patent and literature review (2013-2019)
Bua S
Expert Opinion on Therapeutic Patents 2019; 29: 829-839
82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792
82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Angeli A
Expert Opinion on Therapeutic Patents 2019; 29: 793-803
82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792
82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 793-803
82535 Rho-kinase inhibitors in the management of glaucoma
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 817-827
82353 Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 805-815
82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 753-759
82395 Diagnostic markers for glaucoma: a patent and literature review (2013-2019)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 829-839
82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792

Issue 20-4

Change Issue


advertisement

Oculus